Cargando…
Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial
BACKGROUND: Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor (Empagliflozin) is an effective drug in controlling blood glucose through predominantly glycosuria. Glycosuria increases the risk of genitourinary infections in diabetes. This study was aimed to establish the safety and efficacy of Empagl...
Autores principales: | Aamir, Azizul Hasan, Raja, Umar Yousaf, Qureshi, Faisal Masood, Asghar, Ali, Mahar, Saeed Ahmed, Ahmed, Ibrar, Ghaffar, Tahir, Zafar, Jamal, Hasan, Mohammad Imtiaz, Riaz, Amna, Raza, Syed Abbas, Khosa, Irshad Ahmed, Khan, Jahanzeb, Baqar, Jaffer Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703399/ https://www.ncbi.nlm.nih.gov/pubmed/36443769 http://dx.doi.org/10.1186/s12902-022-01213-1 |
Ejemplares similares
-
Asymptomatic urinary tract infections and associated risk factors in Pakistani Muslim type 2 diabetic patients
por: Aamir, Azizul Hasan, et al.
Publicado: (2021) -
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022) -
Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan
por: Aamir, Azizul Hasan, et al.
Publicado: (2019) -
Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022) -
Exploring Identity in Muslim Moroccan and Pakistani Immigrant Women
por: Giuliani, Cristina, et al.
Publicado: (2015)